DADC
ACHN

D.A. Davidson & Co’s Achillion Pharmaceuticals ACHN Stock Holding History

D.A. Davidson & Co’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-114,612
Closed -$330K – 1164
2017
Q4 		$330K Sell
114,612
-18,394
-14% -$66.8K 0.01% 806
2017
Q3 		$597K Sell
133,006
-9,000
-6% -$40K 0.01% 628
2017
Q2 		$651K Buy
142,006
+8,087
+6% +$32.5K 0.01% 549
2017
Q1 		$563K Buy
133,919
+37,905
+39% +$157K 0.01% 576
2016
Q4 		$396K Buy
+96,014
New +$510K 0.01% 730

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

D.A. Davidson & Co's ACHN Position: Q1 2018 in Review

D.A. Davidson & Co sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 114,612 shares — an estimated $330K sold.

D.A. Davidson & Co first reported a position in ACHN in Q4 2016 and held it in 5 quarters. The position peaked at $651K in Q2 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • D.A. Davidson & Co reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 114,612 Achillion Pharmaceuticals shares in Q1 2018, an estimated $330K.
  • D.A. Davidson & Co first reported a position in Achillion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • D.A. Davidson & Co's Achillion Pharmaceuticals position peaked at $651K in Q2 2017.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on D.A. Davidson & Co's 13F filing for Q1 2018, filed 4 May 2018.